公开(公告)号：US12097172B2

公开(公告)日：2024-09-24

申请号：US17679842

申请日：2022-02-24

申请人： THE CHILDREN'S MEDICAL CENTER CORPORATION ,  DOMPE FARMACEUTICI S.P.A.

发明人： Paolo Fiorina ,  Roberto Bassi ,  Andrea Vergani ,  Marcello Allegretti

IPC分类号： A61K31/18 ,  A61K31/426 ,  A61K45/06 ,  A61P3/10 ,  A61P13/12 ,  G01N33/68

CPC分类号： A61K31/18 ,  A61K31/426 ,  A61K45/06 ,  A61P3/10 ,  A61P13/12 ,  G01N33/68 ,  A61K31/18 ,  A61K2300/00

摘要： Embodiments herein disclose methods relating to diabetic nephropathy (DN); methods for preventing the onset and also for preventing the progressing of DN, as well as the treatment of DN in diabetic subjects comprising administering reparixin and/or ladarixin which are inhibitors of CXCL8 receptor CXCR1 and CXCR2 activation.

公开(公告)号：US20240307382A1

公开(公告)日：2024-09-19

申请号：US18330185

申请日：2023-06-06

申请人： Calico Life Sciences LLC ,  AbbVie Inc.

发明人： Kathleen Ann Martin ,  Carmela Sidrauski ,  Jennifer M. Frost ,  Marina Pliushchev ,  Yunsong Tong ,  Lawrence A. Black ,  Xiangdong Xu ,  Lei Shi ,  Qingwei Zhang ,  SeungWon Chung ,  Ramzi Farah Sweis ,  Michael J. Dart ,  John T. Randolph ,  Kathleen J. Murauski

IPC分类号： A61K31/4965 ,  A61K31/196 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/472 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5355 ,  A61K45/06 ,  C07C233/62 ,  C07D217/26 ,  C07D231/14 ,  C07D237/20 ,  C07D241/20 ,  C07D249/10 ,  C07D261/18 ,  C07D263/34 ,  C07D275/03 ,  C07D277/56 ,  C07D285/06 ,  C07D307/68 ,  C07D317/46 ,  C07D333/38 ,  C07D401/04 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

CPC分类号： A61K31/4965 ,  A61K31/196 ,  A61K31/341 ,  A61K31/36 ,  A61K31/381 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/426 ,  A61K31/437 ,  A61K31/4427 ,  A61K31/472 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/5355 ,  A61K45/06 ,  C07C233/62 ,  C07D217/26 ,  C07D231/14 ,  C07D237/20 ,  C07D241/20 ,  C07D249/10 ,  C07D261/18 ,  C07D263/34 ,  C07D275/03 ,  C07D277/56 ,  C07D285/06 ,  C07D307/68 ,  C07D317/46 ,  C07D333/38 ,  C07D401/04 ,  C07D413/04 ,  C07D471/04 ,  C07D487/04 ,  C07D495/04

摘要： Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

公开(公告)号：US20240285589A1

公开(公告)日：2024-08-29

申请号：US18564955

申请日：2021-05-28

申请人： Theodore HENDERSON

发明人： Theodore HENDERSON

IPC分类号： A61K31/426 ,  A61K31/52 ,  A61K31/522 ,  A61P31/12

CPC分类号： A61K31/426 ,  A61K31/52 ,  A61K31/522 ,  A61P31/12

摘要： The disclosure relates to methods for treating a virally induced functional disorder (VIFD), a functional somatic syndrome (FSS) and/or a herpes-family virus by administering a therapeutically-effective combination of an antiviral compound and nitazoxanide. The disclosure is further related to pharmaceutical compositions comprising a combination of an antiviral compound and nitazoxanide.

公开(公告)号：US20240270701A1

公开(公告)日：2024-08-15

申请号：US18694362

申请日：2022-09-22

申请人： Curasen Therapeutics, Inc.

发明人： Jiaxin Yu ,  Anthony P. Ford ,  Wei Chen

IPC分类号： C07D241/42 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/417 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/47 ,  A61K31/498 ,  A61K31/517 ,  C07D209/34 ,  C07D213/38 ,  C07D213/61 ,  C07D213/73 ,  C07D215/14 ,  C07D215/233 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D237/20 ,  C07D239/42 ,  C07D239/74 ,  C07D277/40 ,  C07D277/68 ,  C07D471/04

CPC分类号： C07D241/42 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/417 ,  A61K31/426 ,  A61K31/437 ,  A61K31/44 ,  A61K31/47 ,  A61K31/498 ,  A61K31/517 ,  C07D209/34 ,  C07D213/38 ,  C07D213/61 ,  C07D213/73 ,  C07D215/14 ,  C07D215/233 ,  C07D231/56 ,  C07D235/08 ,  C07D235/26 ,  C07D237/20 ,  C07D239/42 ,  C07D239/74 ,  C07D277/40 ,  C07D277/68 ,  C07D471/04

摘要： The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with modulation of beta-adrenergic receptors. In addition, the disclosure provides methods of using the compounds described herein for the treatment of diseases associated with an adrenergic receptor, including but not limited to neurodegenerative diseases and disorders.

公开(公告)号：US20240254066A1

公开(公告)日：2024-08-01

申请号：US18560341

申请日：2022-05-12

申请人： GW Research Limited

发明人： Alan James SILCOCK ,  Karen Ka-Yen TSE ,  Paul Stuart HINCHLIFFE ,  Andrew SHARPE ,  Iain David SIMPSON ,  Joanne PEACH ,  Stefano LEVANTO ,  Antoine MILLET ,  Inderjit Singh MANN

IPC分类号： C07C43/295 ,  A61K31/05 ,  A61K31/055 ,  A61K31/075 ,  A61K31/085 ,  A61K31/137 ,  A61K31/277 ,  A61K31/351 ,  A61K31/36 ,  A61K31/415 ,  A61K31/42 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/505 ,  A61P25/08 ,  C07C29/143 ,  C07C35/18 ,  C07C37/48 ,  C07C37/56 ,  C07C39/23 ,  C07C39/42 ,  C07C41/03 ,  C07C41/26 ,  C07C41/30 ,  C07C43/23 ,  C07C67/08 ,  C07C67/287 ,  C07C69/94 ,  C07C213/08 ,  C07C215/50 ,  C07C253/30 ,  C07C255/36 ,  C07C303/30 ,  C07C309/87 ,  C07D211/70 ,  C07D213/30 ,  C07D213/61 ,  C07D213/64 ,  C07D213/65 ,  C07D231/12 ,  C07D239/34 ,  C07D261/08 ,  C07D277/24 ,  C07D309/22 ,  C07D317/54

CPC分类号： C07C43/295 ,  A61K31/05 ,  A61K31/055 ,  A61K31/075 ,  A61K31/085 ,  A61K31/137 ,  A61K31/277 ,  A61K31/351 ,  A61K31/36 ,  A61K31/415 ,  A61K31/42 ,  A61K31/426 ,  A61K31/4418 ,  A61K31/505 ,  A61P25/08 ,  C07C29/143 ,  C07C35/18 ,  C07C37/48 ,  C07C37/56 ,  C07C39/23 ,  C07C39/42 ,  C07C41/03 ,  C07C41/26 ,  C07C41/30 ,  C07C43/23 ,  C07C67/08 ,  C07C67/287 ,  C07C69/94 ,  C07C213/08 ,  C07C215/50 ,  C07C253/30 ,  C07C255/36 ,  C07C303/30 ,  C07C309/87 ,  C07D211/70 ,  C07D213/30 ,  C07D213/61 ,  C07D213/64 ,  C07D213/65 ,  C07D231/12 ,  C07D239/34 ,  C07D261/08 ,  C07D277/24 ,  C07D309/22 ,  C07D317/54 ,  C07C2601/02 ,  C07C2601/10 ,  C07C2601/16

摘要： The present invention relates to a group of resorcinol derivatives as a pharmaceutically active compounds and methods of preparation thereof. Resorcinol derivatives have been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the resorcinol derivative of the invention.

公开(公告)号：US20240245656A1

公开(公告)日：2024-07-25

申请号：US18628068

申请日：2024-04-05

申请人： vTv Therapeutics LLC

发明人： Jennifer L.R. FREEMAN ,  Maria Carmen VALCARCE LOPEZ

IPC分类号： A61K31/426 ,  A61K9/00 ,  A61P3/10

CPC分类号： A61K31/426 ,  A61K9/0053 ,  A61P3/10

摘要： Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.

公开(公告)号：US12036210B2

公开(公告)日：2024-07-16

申请号：US17575175

申请日：2022-01-13

申请人： ATROGI AB

发明人： Benjamin Pelcman ,  Tore Bengtsson

IPC分类号： A61K31/4412 ,  A61K31/426 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  A61P3/10 ,  C07D213/38 ,  C07D213/64 ,  C07D239/36 ,  C07D277/24

CPC分类号： A61K31/4412 ,  A61K31/426 ,  A61K31/44 ,  A61K31/505 ,  A61K45/06 ,  A61P3/10 ,  C07D213/38 ,  C07D213/64 ,  C07D239/36 ,  C07D277/24

摘要： There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.

公开(公告)号：US20240226070A1

公开(公告)日：2024-07-11

申请号：US18285841

申请日：2022-04-06

申请人： UR-1 Therapeutics, Inc.

发明人： Lindsay Rosenwald ,  Lei Zheng

IPC分类号： A61K31/426 ,  A61K31/519 ,  A61K38/44 ,  A61K45/06 ,  A61P13/12

CPC分类号： A61K31/426 ,  A61K31/519 ,  A61K38/44 ,  A61K45/06 ,  A61P13/12 ,  C12Y107/03003

摘要： Provided herein are pharmaceutical compositions including a URAT1 inhibitor and methods of use thereof. The pharmaceutical compositions can include dotinurad, a xanthine oxidase inhibitor, such as allopurinol and/or a sodium-glucose cotransporter-2 inhibitor. The pharmaceutical compositions described herein can be used for the treatment of diseases and conditions related to uric acid, including chronic kidney disease.

公开(公告)号：US11999759B2

公开(公告)日：2024-06-04

申请号：US17520365

申请日：2021-11-05

申请人： Qpex Biopharma, Inc.

发明人： Scott J. Hecker ,  Raja K. Reddy ,  Tomasz Glinka ,  Olga Rodny

IPC分类号： C07F5/02 ,  A61K31/04 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/69 ,  A61K45/06 ,  A61P31/00 ,  A61P31/04 ,  C07F5/04 ,  C07F5/05

CPC分类号： C07F5/05 ,  A61K31/407 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/69 ,  A61K45/06 ,  A61P31/00 ,  A61P31/04 ,  C07F5/025 ,  Y02A50/30

摘要： Disclosed herein are antimicrobial compounds compositions, pharmaceutical compositions, the method of use and preparation thereof. Some embodiments relate to boronic acid derivatives and their use as therapeutic agents, for example, β-lactamase inhibitors (BLIs).

公开(公告)号：US11998546B2

公开(公告)日：2024-06-04

申请号：US16344453

申请日：2017-10-27

申请人： ACETYLON PHARMACEUTICALS, INC.

发明人： Pengyu Huang ,  Steven Quayle

IPC分类号： C07D239/28 ,  A61K31/337 ,  A61K31/426 ,  A61K31/427 ,  A61K31/505 ,  A61P35/00 ,  C07D417/06

CPC分类号： A61K31/505 ,  A61K31/337 ,  A61K31/426 ,  A61P35/00

摘要： The present disclosure relates to a pharmaceutical combination comprising (a) a histone deacetylase 6 inhibitor and (b) an epothilone, including combined preparations and pharmaceutical compositions thereof; uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.